nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—SIGMAR1—Raloxifene—osteoporosis	0.262	0.384	CbGbCtD
Amantadine—SLC22A1—Estropipate—osteoporosis	0.177	0.261	CbGbCtD
Amantadine—SLC22A2—Estradiol—osteoporosis	0.0848	0.125	CbGbCtD
Amantadine—SLC22A1—Estradiol—osteoporosis	0.0737	0.108	CbGbCtD
Amantadine—ABCB1—Ethinyl Estradiol—osteoporosis	0.035	0.0514	CbGbCtD
Amantadine—ABCB1—Conjugated Estrogens—osteoporosis	0.0257	0.0378	CbGbCtD
Amantadine—ABCB1—Estradiol—osteoporosis	0.0226	0.0332	CbGbCtD
Amantadine—SIGMAR1—Levonorgestrel—Ethinyl Estradiol—osteoporosis	0.00275	1	CbGdCrCtD
Amantadine—Convulsion—Pamidronate—osteoporosis	0.000428	0.00161	CcSEcCtD
Amantadine—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000426	0.00161	CcSEcCtD
Amantadine—Hypertension—Pamidronate—osteoporosis	0.000426	0.00161	CcSEcCtD
Amantadine—Tension—Conjugated Estrogens—osteoporosis	0.000426	0.00161	CcSEcCtD
Amantadine—Vision blurred—Zoledronate—osteoporosis	0.000425	0.0016	CcSEcCtD
Amantadine—Diarrhoea—Etidronic acid—osteoporosis	0.000424	0.0016	CcSEcCtD
Amantadine—Body temperature increased—Estropipate—osteoporosis	0.000424	0.0016	CcSEcCtD
Amantadine—Feeling abnormal—Ibandronate—osteoporosis	0.000424	0.0016	CcSEcCtD
Amantadine—Tremor—Zoledronate—osteoporosis	0.000423	0.00159	CcSEcCtD
Amantadine—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000422	0.00159	CcSEcCtD
Amantadine—Nervousness—Conjugated Estrogens—osteoporosis	0.000422	0.00159	CcSEcCtD
Amantadine—Anxiety—Pamidronate—osteoporosis	0.000419	0.00158	CcSEcCtD
Amantadine—Body temperature increased—Alendronate—osteoporosis	0.000418	0.00158	CcSEcCtD
Amantadine—Nervous system disorder—Risedronate—osteoporosis	0.000416	0.00157	CcSEcCtD
Amantadine—Agitation—Zoledronate—osteoporosis	0.000415	0.00156	CcSEcCtD
Amantadine—Skin disorder—Risedronate—osteoporosis	0.000412	0.00155	CcSEcCtD
Amantadine—Body temperature increased—Raloxifene—osteoporosis	0.000411	0.00155	CcSEcCtD
Amantadine—Vision blurred—Conjugated Estrogens—osteoporosis	0.000409	0.00154	CcSEcCtD
Amantadine—Body temperature increased—Ibandronate—osteoporosis	0.000407	0.00153	CcSEcCtD
Amantadine—Confusional state—Pamidronate—osteoporosis	0.000406	0.00153	CcSEcCtD
Amantadine—Leukopenia—Zoledronate—osteoporosis	0.000404	0.00152	CcSEcCtD
Amantadine—Oedema—Pamidronate—osteoporosis	0.000403	0.00152	CcSEcCtD
Amantadine—Anaphylactic shock—Pamidronate—osteoporosis	0.000403	0.00152	CcSEcCtD
Amantadine—Palpitations—Zoledronate—osteoporosis	0.000399	0.0015	CcSEcCtD
Amantadine—Body temperature increased—Calcitriol—osteoporosis	0.000398	0.0015	CcSEcCtD
Amantadine—Hypersensitivity—Estropipate—osteoporosis	0.000395	0.00149	CcSEcCtD
Amantadine—Nervous system disorder—Pamidronate—osteoporosis	0.000395	0.00149	CcSEcCtD
Amantadine—Urinary tract disorder—Estradiol—osteoporosis	0.000394	0.00149	CcSEcCtD
Amantadine—Vomiting—Etidronic acid—osteoporosis	0.000394	0.00149	CcSEcCtD
Amantadine—Oedema peripheral—Estradiol—osteoporosis	0.000393	0.00148	CcSEcCtD
Amantadine—Tachycardia—Pamidronate—osteoporosis	0.000393	0.00148	CcSEcCtD
Amantadine—Urethral disorder—Estradiol—osteoporosis	0.000391	0.00148	CcSEcCtD
Amantadine—Rash—Etidronic acid—osteoporosis	0.000391	0.00147	CcSEcCtD
Amantadine—Convulsion—Zoledronate—osteoporosis	0.000391	0.00147	CcSEcCtD
Amantadine—Dermatitis—Etidronic acid—osteoporosis	0.000391	0.00147	CcSEcCtD
Amantadine—Hyperhidrosis—Pamidronate—osteoporosis	0.00039	0.00147	CcSEcCtD
Amantadine—Hypertension—Zoledronate—osteoporosis	0.000389	0.00147	CcSEcCtD
Amantadine—Hypersensitivity—Alendronate—osteoporosis	0.000389	0.00147	CcSEcCtD
Amantadine—Headache—Etidronic acid—osteoporosis	0.000388	0.00147	CcSEcCtD
Amantadine—Asthenia—Estropipate—osteoporosis	0.000385	0.00145	CcSEcCtD
Amantadine—Visual impairment—Estradiol—osteoporosis	0.000385	0.00145	CcSEcCtD
Amantadine—Anorexia—Pamidronate—osteoporosis	0.000384	0.00145	CcSEcCtD
Amantadine—Palpitations—Conjugated Estrogens—osteoporosis	0.000384	0.00145	CcSEcCtD
Amantadine—Insomnia—Risedronate—osteoporosis	0.000383	0.00145	CcSEcCtD
Amantadine—Anxiety—Zoledronate—osteoporosis	0.000383	0.00144	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000381	0.00144	CcSEcCtD
Amantadine—Paraesthesia—Risedronate—osteoporosis	0.000381	0.00144	CcSEcCtD
Amantadine—Pruritus—Estropipate—osteoporosis	0.00038	0.00143	CcSEcCtD
Amantadine—Asthenia—Alendronate—osteoporosis	0.000379	0.00143	CcSEcCtD
Amantadine—Hypersensitivity—Ibandronate—osteoporosis	0.000379	0.00143	CcSEcCtD
Amantadine—Dyspnoea—Risedronate—osteoporosis	0.000378	0.00143	CcSEcCtD
Amantadine—Hypotension—Pamidronate—osteoporosis	0.000377	0.00142	CcSEcCtD
Amantadine—Convulsion—Conjugated Estrogens—osteoporosis	0.000376	0.00142	CcSEcCtD
Amantadine—Dry mouth—Zoledronate—osteoporosis	0.000376	0.00142	CcSEcCtD
Amantadine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000375	0.00142	CcSEcCtD
Amantadine—Fatigue—Ethinyl Estradiol—osteoporosis	0.000375	0.00141	CcSEcCtD
Amantadine—Pruritus—Alendronate—osteoporosis	0.000374	0.00141	CcSEcCtD
Amantadine—Dyspepsia—Risedronate—osteoporosis	0.000373	0.00141	CcSEcCtD
Amantadine—Eye disorder—Estradiol—osteoporosis	0.000373	0.00141	CcSEcCtD
Amantadine—Constipation—Ethinyl Estradiol—osteoporosis	0.000372	0.0014	CcSEcCtD
Amantadine—Confusional state—Zoledronate—osteoporosis	0.000371	0.0014	CcSEcCtD
Amantadine—Hypersensitivity—Calcitriol—osteoporosis	0.000371	0.0014	CcSEcCtD
Amantadine—Cardiac disorder—Estradiol—osteoporosis	0.000371	0.0014	CcSEcCtD
Amantadine—Asthenia—Ibandronate—osteoporosis	0.000369	0.00139	CcSEcCtD
Amantadine—Anxiety—Conjugated Estrogens—osteoporosis	0.000369	0.00139	CcSEcCtD
Amantadine—Nausea—Etidronic acid—osteoporosis	0.000368	0.00139	CcSEcCtD
Amantadine—Anaphylactic shock—Zoledronate—osteoporosis	0.000368	0.00139	CcSEcCtD
Amantadine—Oedema—Zoledronate—osteoporosis	0.000368	0.00139	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000367	0.00139	CcSEcCtD
Amantadine—Diarrhoea—Estropipate—osteoporosis	0.000367	0.00138	CcSEcCtD
Amantadine—Gastrointestinal disorder—Risedronate—osteoporosis	0.000366	0.00138	CcSEcCtD
Amantadine—Fatigue—Risedronate—osteoporosis	0.000366	0.00138	CcSEcCtD
Amantadine—Insomnia—Pamidronate—osteoporosis	0.000365	0.00137	CcSEcCtD
Amantadine—Pruritus—Ibandronate—osteoporosis	0.000364	0.00137	CcSEcCtD
Amantadine—Constipation—Risedronate—osteoporosis	0.000363	0.00137	CcSEcCtD
Amantadine—Angiopathy—Estradiol—osteoporosis	0.000362	0.00137	CcSEcCtD
Amantadine—Paraesthesia—Pamidronate—osteoporosis	0.000362	0.00137	CcSEcCtD
Amantadine—Diarrhoea—Alendronate—osteoporosis	0.000362	0.00136	CcSEcCtD
Amantadine—Asthenia—Calcitriol—osteoporosis	0.000361	0.00136	CcSEcCtD
Amantadine—Nervous system disorder—Zoledronate—osteoporosis	0.000361	0.00136	CcSEcCtD
Amantadine—Mediastinal disorder—Estradiol—osteoporosis	0.00036	0.00136	CcSEcCtD
Amantadine—Dyspnoea—Pamidronate—osteoporosis	0.000359	0.00136	CcSEcCtD
Amantadine—Tachycardia—Zoledronate—osteoporosis	0.000359	0.00136	CcSEcCtD
Amantadine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000358	0.00135	CcSEcCtD
Amantadine—Somnolence—Pamidronate—osteoporosis	0.000358	0.00135	CcSEcCtD
Amantadine—Skin disorder—Zoledronate—osteoporosis	0.000358	0.00135	CcSEcCtD
Amantadine—Pruritus—Calcitriol—osteoporosis	0.000356	0.00134	CcSEcCtD
Amantadine—Hyperhidrosis—Zoledronate—osteoporosis	0.000356	0.00134	CcSEcCtD
Amantadine—Diarrhoea—Raloxifene—osteoporosis	0.000356	0.00134	CcSEcCtD
Amantadine—Dyspepsia—Pamidronate—osteoporosis	0.000355	0.00134	CcSEcCtD
Amantadine—Dizziness—Estropipate—osteoporosis	0.000355	0.00134	CcSEcCtD
Amantadine—Oedema—Conjugated Estrogens—osteoporosis	0.000354	0.00134	CcSEcCtD
Amantadine—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000354	0.00134	CcSEcCtD
Amantadine—Alopecia—Estradiol—osteoporosis	0.000353	0.00133	CcSEcCtD
Amantadine—Diarrhoea—Ibandronate—osteoporosis	0.000352	0.00133	CcSEcCtD
Amantadine—Anorexia—Zoledronate—osteoporosis	0.000351	0.00132	CcSEcCtD
Amantadine—Decreased appetite—Pamidronate—osteoporosis	0.00035	0.00132	CcSEcCtD
Amantadine—Mental disorder—Estradiol—osteoporosis	0.00035	0.00132	CcSEcCtD
Amantadine—Dizziness—Alendronate—osteoporosis	0.000349	0.00132	CcSEcCtD
Amantadine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000348	0.00131	CcSEcCtD
Amantadine—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000348	0.00131	CcSEcCtD
Amantadine—Malnutrition—Estradiol—osteoporosis	0.000348	0.00131	CcSEcCtD
Amantadine—Fatigue—Pamidronate—osteoporosis	0.000347	0.00131	CcSEcCtD
Amantadine—Tachycardia—Conjugated Estrogens—osteoporosis	0.000346	0.0013	CcSEcCtD
Amantadine—Constipation—Pamidronate—osteoporosis	0.000345	0.0013	CcSEcCtD
Amantadine—Diarrhoea—Calcitriol—osteoporosis	0.000345	0.0013	CcSEcCtD
Amantadine—Skin disorder—Conjugated Estrogens—osteoporosis	0.000344	0.0013	CcSEcCtD
Amantadine—Hypotension—Zoledronate—osteoporosis	0.000344	0.0013	CcSEcCtD
Amantadine—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000344	0.0013	CcSEcCtD
Amantadine—Dizziness—Raloxifene—osteoporosis	0.000344	0.0013	CcSEcCtD
Amantadine—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000343	0.00129	CcSEcCtD
Amantadine—Tension—Estradiol—osteoporosis	0.000341	0.00129	CcSEcCtD
Amantadine—Vomiting—Estropipate—osteoporosis	0.000341	0.00129	CcSEcCtD
Amantadine—Dizziness—Ibandronate—osteoporosis	0.00034	0.00128	CcSEcCtD
Amantadine—Rash—Estropipate—osteoporosis	0.000338	0.00128	CcSEcCtD
Amantadine—Dermatitis—Estropipate—osteoporosis	0.000338	0.00127	CcSEcCtD
Amantadine—Anorexia—Conjugated Estrogens—osteoporosis	0.000338	0.00127	CcSEcCtD
Amantadine—Nervousness—Estradiol—osteoporosis	0.000338	0.00127	CcSEcCtD
Amantadine—Headache—Estropipate—osteoporosis	0.000336	0.00127	CcSEcCtD
Amantadine—Vomiting—Alendronate—osteoporosis	0.000336	0.00127	CcSEcCtD
Amantadine—Body temperature increased—Risedronate—osteoporosis	0.000335	0.00126	CcSEcCtD
Amantadine—Rash—Alendronate—osteoporosis	0.000333	0.00126	CcSEcCtD
Amantadine—Insomnia—Zoledronate—osteoporosis	0.000333	0.00126	CcSEcCtD
Amantadine—Dermatitis—Alendronate—osteoporosis	0.000333	0.00126	CcSEcCtD
Amantadine—Feeling abnormal—Pamidronate—osteoporosis	0.000332	0.00125	CcSEcCtD
Amantadine—Hypotension—Conjugated Estrogens—osteoporosis	0.000331	0.00125	CcSEcCtD
Amantadine—Headache—Alendronate—osteoporosis	0.000331	0.00125	CcSEcCtD
Amantadine—Paraesthesia—Zoledronate—osteoporosis	0.000331	0.00125	CcSEcCtD
Amantadine—Vomiting—Raloxifene—osteoporosis	0.00033	0.00125	CcSEcCtD
Amantadine—Dyspnoea—Zoledronate—osteoporosis	0.000328	0.00124	CcSEcCtD
Amantadine—Rash—Raloxifene—osteoporosis	0.000328	0.00124	CcSEcCtD
Amantadine—Dermatitis—Raloxifene—osteoporosis	0.000327	0.00123	CcSEcCtD
Amantadine—Somnolence—Zoledronate—osteoporosis	0.000327	0.00123	CcSEcCtD
Amantadine—Vomiting—Ibandronate—osteoporosis	0.000327	0.00123	CcSEcCtD
Amantadine—Tremor—Estradiol—osteoporosis	0.000326	0.00123	CcSEcCtD
Amantadine—Headache—Raloxifene—osteoporosis	0.000326	0.00123	CcSEcCtD
Amantadine—Rash—Ibandronate—osteoporosis	0.000324	0.00122	CcSEcCtD
Amantadine—Dermatitis—Ibandronate—osteoporosis	0.000324	0.00122	CcSEcCtD
Amantadine—Dyspepsia—Zoledronate—osteoporosis	0.000324	0.00122	CcSEcCtD
Amantadine—Headache—Ibandronate—osteoporosis	0.000322	0.00122	CcSEcCtD
Amantadine—Insomnia—Conjugated Estrogens—osteoporosis	0.000321	0.00121	CcSEcCtD
Amantadine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.00032	0.00121	CcSEcCtD
Amantadine—Vomiting—Calcitriol—osteoporosis	0.00032	0.00121	CcSEcCtD
Amantadine—Decreased appetite—Zoledronate—osteoporosis	0.00032	0.00121	CcSEcCtD
Amantadine—Agitation—Estradiol—osteoporosis	0.000319	0.0012	CcSEcCtD
Amantadine—Nausea—Estropipate—osteoporosis	0.000319	0.0012	CcSEcCtD
Amantadine—Body temperature increased—Pamidronate—osteoporosis	0.000319	0.0012	CcSEcCtD
Amantadine—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000318	0.0012	CcSEcCtD
Amantadine—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000318	0.0012	CcSEcCtD
Amantadine—Rash—Calcitriol—osteoporosis	0.000318	0.0012	CcSEcCtD
Amantadine—Fatigue—Zoledronate—osteoporosis	0.000317	0.0012	CcSEcCtD
Amantadine—Dermatitis—Calcitriol—osteoporosis	0.000317	0.0012	CcSEcCtD
Amantadine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000316	0.00119	CcSEcCtD
Amantadine—Headache—Calcitriol—osteoporosis	0.000316	0.00119	CcSEcCtD
Amantadine—Somnolence—Conjugated Estrogens—osteoporosis	0.000315	0.00119	CcSEcCtD
Amantadine—Constipation—Zoledronate—osteoporosis	0.000315	0.00119	CcSEcCtD
Amantadine—Nausea—Alendronate—osteoporosis	0.000314	0.00118	CcSEcCtD
Amantadine—Hypersensitivity—Risedronate—osteoporosis	0.000312	0.00118	CcSEcCtD
Amantadine—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000312	0.00118	CcSEcCtD
Amantadine—Asthenia—Ethinyl Estradiol—osteoporosis	0.000312	0.00118	CcSEcCtD
Amantadine—Nausea—Raloxifene—osteoporosis	0.000309	0.00116	CcSEcCtD
Amantadine—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000308	0.00116	CcSEcCtD
Amantadine—Pruritus—Ethinyl Estradiol—osteoporosis	0.000308	0.00116	CcSEcCtD
Amantadine—Palpitations—Estradiol—osteoporosis	0.000307	0.00116	CcSEcCtD
Amantadine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000306	0.00115	CcSEcCtD
Amantadine—Fatigue—Conjugated Estrogens—osteoporosis	0.000306	0.00115	CcSEcCtD
Amantadine—Nausea—Ibandronate—osteoporosis	0.000306	0.00115	CcSEcCtD
Amantadine—Asthenia—Risedronate—osteoporosis	0.000304	0.00115	CcSEcCtD
Amantadine—Feeling abnormal—Zoledronate—osteoporosis	0.000303	0.00114	CcSEcCtD
Amantadine—Constipation—Conjugated Estrogens—osteoporosis	0.000303	0.00114	CcSEcCtD
Amantadine—Hypertension—Estradiol—osteoporosis	0.0003	0.00113	CcSEcCtD
Amantadine—Pruritus—Risedronate—osteoporosis	0.0003	0.00113	CcSEcCtD
Amantadine—Nausea—Calcitriol—osteoporosis	0.000299	0.00113	CcSEcCtD
Amantadine—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000298	0.00112	CcSEcCtD
Amantadine—Hypersensitivity—Pamidronate—osteoporosis	0.000297	0.00112	CcSEcCtD
Amantadine—Anxiety—Estradiol—osteoporosis	0.000295	0.00111	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000294	0.00111	CcSEcCtD
Amantadine—Body temperature increased—Zoledronate—osteoporosis	0.000291	0.0011	CcSEcCtD
Amantadine—Diarrhoea—Risedronate—osteoporosis	0.00029	0.00109	CcSEcCtD
Amantadine—Dry mouth—Estradiol—osteoporosis	0.000289	0.00109	CcSEcCtD
Amantadine—Asthenia—Pamidronate—osteoporosis	0.000289	0.00109	CcSEcCtD
Amantadine—Dizziness—Ethinyl Estradiol—osteoporosis	0.000288	0.00108	CcSEcCtD
Amantadine—Confusional state—Estradiol—osteoporosis	0.000286	0.00108	CcSEcCtD
Amantadine—Pruritus—Pamidronate—osteoporosis	0.000285	0.00108	CcSEcCtD
Amantadine—Anaphylactic shock—Estradiol—osteoporosis	0.000284	0.00107	CcSEcCtD
Amantadine—Oedema—Estradiol—osteoporosis	0.000284	0.00107	CcSEcCtD
Amantadine—Dizziness—Risedronate—osteoporosis	0.00028	0.00106	CcSEcCtD
Amantadine—Body temperature increased—Conjugated Estrogens—osteoporosis	0.00028	0.00106	CcSEcCtD
Amantadine—Nervous system disorder—Estradiol—osteoporosis	0.000278	0.00105	CcSEcCtD
Amantadine—Tachycardia—Estradiol—osteoporosis	0.000277	0.00104	CcSEcCtD
Amantadine—Vomiting—Ethinyl Estradiol—osteoporosis	0.000276	0.00104	CcSEcCtD
Amantadine—Diarrhoea—Pamidronate—osteoporosis	0.000276	0.00104	CcSEcCtD
Amantadine—Skin disorder—Estradiol—osteoporosis	0.000276	0.00104	CcSEcCtD
Amantadine—Hyperhidrosis—Estradiol—osteoporosis	0.000274	0.00103	CcSEcCtD
Amantadine—Rash—Ethinyl Estradiol—osteoporosis	0.000274	0.00103	CcSEcCtD
Amantadine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000274	0.00103	CcSEcCtD
Amantadine—Headache—Ethinyl Estradiol—osteoporosis	0.000272	0.00103	CcSEcCtD
Amantadine—Hypersensitivity—Zoledronate—osteoporosis	0.000271	0.00102	CcSEcCtD
Amantadine—Vomiting—Risedronate—osteoporosis	0.00027	0.00102	CcSEcCtD
Amantadine—Rash—Risedronate—osteoporosis	0.000267	0.00101	CcSEcCtD
Amantadine—Dermatitis—Risedronate—osteoporosis	0.000267	0.00101	CcSEcCtD
Amantadine—Dizziness—Pamidronate—osteoporosis	0.000267	0.00101	CcSEcCtD
Amantadine—Headache—Risedronate—osteoporosis	0.000266	0.001	CcSEcCtD
Amantadine—Asthenia—Zoledronate—osteoporosis	0.000264	0.000996	CcSEcCtD
Amantadine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000261	0.000985	CcSEcCtD
Amantadine—Pruritus—Zoledronate—osteoporosis	0.00026	0.000982	CcSEcCtD
Amantadine—Nausea—Ethinyl Estradiol—osteoporosis	0.000258	0.000974	CcSEcCtD
Amantadine—Insomnia—Estradiol—osteoporosis	0.000257	0.000968	CcSEcCtD
Amantadine—Vomiting—Pamidronate—osteoporosis	0.000256	0.000967	CcSEcCtD
Amantadine—Paraesthesia—Estradiol—osteoporosis	0.000255	0.000961	CcSEcCtD
Amantadine—Asthenia—Conjugated Estrogens—osteoporosis	0.000254	0.000959	CcSEcCtD
Amantadine—Rash—Pamidronate—osteoporosis	0.000254	0.000959	CcSEcCtD
Amantadine—Dermatitis—Pamidronate—osteoporosis	0.000254	0.000958	CcSEcCtD
Amantadine—Dyspnoea—Estradiol—osteoporosis	0.000253	0.000954	CcSEcCtD
Amantadine—Headache—Pamidronate—osteoporosis	0.000252	0.000952	CcSEcCtD
Amantadine—Somnolence—Estradiol—osteoporosis	0.000252	0.000951	CcSEcCtD
Amantadine—Diarrhoea—Zoledronate—osteoporosis	0.000252	0.00095	CcSEcCtD
Amantadine—Nausea—Risedronate—osteoporosis	0.000252	0.00095	CcSEcCtD
Amantadine—Pruritus—Conjugated Estrogens—osteoporosis	0.000251	0.000946	CcSEcCtD
Amantadine—Dyspepsia—Estradiol—osteoporosis	0.00025	0.000942	CcSEcCtD
Amantadine—Decreased appetite—Estradiol—osteoporosis	0.000247	0.00093	CcSEcCtD
Amantadine—Gastrointestinal disorder—Estradiol—osteoporosis	0.000245	0.000924	CcSEcCtD
Amantadine—Fatigue—Estradiol—osteoporosis	0.000245	0.000923	CcSEcCtD
Amantadine—Dizziness—Zoledronate—osteoporosis	0.000243	0.000918	CcSEcCtD
Amantadine—Constipation—Estradiol—osteoporosis	0.000243	0.000915	CcSEcCtD
Amantadine—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000243	0.000915	CcSEcCtD
Amantadine—Nausea—Pamidronate—osteoporosis	0.000239	0.000903	CcSEcCtD
Amantadine—Dizziness—Conjugated Estrogens—osteoporosis	0.000234	0.000884	CcSEcCtD
Amantadine—Vomiting—Zoledronate—osteoporosis	0.000234	0.000883	CcSEcCtD
Amantadine—Feeling abnormal—Estradiol—osteoporosis	0.000234	0.000882	CcSEcCtD
Amantadine—Rash—Zoledronate—osteoporosis	0.000232	0.000876	CcSEcCtD
Amantadine—Dermatitis—Zoledronate—osteoporosis	0.000232	0.000875	CcSEcCtD
Amantadine—Headache—Zoledronate—osteoporosis	0.000231	0.00087	CcSEcCtD
Amantadine—Vomiting—Conjugated Estrogens—osteoporosis	0.000225	0.00085	CcSEcCtD
Amantadine—Body temperature increased—Estradiol—osteoporosis	0.000224	0.000846	CcSEcCtD
Amantadine—Rash—Conjugated Estrogens—osteoporosis	0.000224	0.000843	CcSEcCtD
Amantadine—Dermatitis—Conjugated Estrogens—osteoporosis	0.000223	0.000842	CcSEcCtD
Amantadine—Headache—Conjugated Estrogens—osteoporosis	0.000222	0.000838	CcSEcCtD
Amantadine—Nausea—Zoledronate—osteoporosis	0.000219	0.000825	CcSEcCtD
Amantadine—Nausea—Conjugated Estrogens—osteoporosis	0.000211	0.000794	CcSEcCtD
Amantadine—Hypersensitivity—Estradiol—osteoporosis	0.000209	0.000788	CcSEcCtD
Amantadine—Asthenia—Estradiol—osteoporosis	0.000204	0.000768	CcSEcCtD
Amantadine—Pruritus—Estradiol—osteoporosis	0.000201	0.000757	CcSEcCtD
Amantadine—Diarrhoea—Estradiol—osteoporosis	0.000194	0.000732	CcSEcCtD
Amantadine—Dizziness—Estradiol—osteoporosis	0.000188	0.000708	CcSEcCtD
Amantadine—Vomiting—Estradiol—osteoporosis	0.00018	0.00068	CcSEcCtD
Amantadine—Rash—Estradiol—osteoporosis	0.000179	0.000675	CcSEcCtD
Amantadine—Dermatitis—Estradiol—osteoporosis	0.000179	0.000674	CcSEcCtD
Amantadine—Headache—Estradiol—osteoporosis	0.000178	0.00067	CcSEcCtD
Amantadine—Nausea—Estradiol—osteoporosis	0.000169	0.000636	CcSEcCtD
Amantadine—GRIN2B—BDNF signaling pathway—IRS1—osteoporosis	0.000153	0.00298	CbGpPWpGaD
Amantadine—GRIN2A—Alzheimers Disease—TNF—osteoporosis	0.000151	0.00294	CbGpPWpGaD
Amantadine—DDC—Metabolism—PKM—osteoporosis	0.000144	0.00281	CbGpPWpGaD
Amantadine—DDC—Metabolism—FDPS—osteoporosis	0.000144	0.00281	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—PTH1R—osteoporosis	0.000142	0.00276	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CALCR—osteoporosis	0.000142	0.00276	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—ADCY5—osteoporosis	0.000139	0.00271	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—IL6R—osteoporosis	0.000138	0.0027	CbGpPWpGaD
Amantadine—DDC—Metabolism—GPD2—osteoporosis	0.000137	0.00266	CbGpPWpGaD
Amantadine—DDC—Metabolism—PGLS—osteoporosis	0.000137	0.00266	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—WNT1—osteoporosis	0.000135	0.00264	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—WNT1—osteoporosis	0.000132	0.00257	CbGpPWpGaD
Amantadine—GRIN1—Alzheimers Disease—TNF—osteoporosis	0.000132	0.00256	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—IL1B—osteoporosis	0.000132	0.00256	CbGpPWpGaD
Amantadine—MAOB—Biological oxidations—POMC—osteoporosis	0.000129	0.0025	CbGpPWpGaD
Amantadine—GRIN2B—Alzheimers Disease—TNF—osteoporosis	0.000128	0.0025	CbGpPWpGaD
Amantadine—DDC—Metabolism—PNP—osteoporosis	0.000125	0.00243	CbGpPWpGaD
Amantadine—DDC—Metabolism—ATIC—osteoporosis	0.000125	0.00243	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—IL1B—osteoporosis	0.000123	0.00239	CbGpPWpGaD
Amantadine—MAOB—Metabolism—FDPS—osteoporosis	0.000121	0.00236	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PKM—osteoporosis	0.000121	0.00236	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—ADCY5—osteoporosis	0.000121	0.00236	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—CNR2—osteoporosis	0.00012	0.00233	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—ADCY5—osteoporosis	0.000118	0.0023	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PGLS—osteoporosis	0.000115	0.00224	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GPD2—osteoporosis	0.000115	0.00224	CbGpPWpGaD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000111	0.00216	CbGpPWpGaD
Amantadine—DDC—Metabolism—CA2—osteoporosis	0.000106	0.00207	CbGpPWpGaD
Amantadine—DDC—Metabolism—OXCT1—osteoporosis	0.000106	0.00207	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—IL1B—osteoporosis	0.000105	0.00205	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PNP—osteoporosis	0.000105	0.00205	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ATIC—osteoporosis	0.000105	0.00205	CbGpPWpGaD
Amantadine—DDC—Metabolism—MGLL—osteoporosis	0.000104	0.00202	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—MYC—osteoporosis	0.000103	0.002	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—TGFB1—osteoporosis	0.000102	0.00199	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—TNF—osteoporosis	9.55e-05	0.00186	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	9.52e-05	0.00185	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—LEP—osteoporosis	9.34e-05	0.00182	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—ANXA2—osteoporosis	9.03e-05	0.00176	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CA2—osteoporosis	8.94e-05	0.00174	CbGpPWpGaD
Amantadine—MAOB—Metabolism—OXCT1—osteoporosis	8.94e-05	0.00174	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—TNF—osteoporosis	8.89e-05	0.00173	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	8.83e-05	0.00172	CbGpPWpGaD
Amantadine—DDC—Metabolism—IDH2—osteoporosis	8.8e-05	0.00171	CbGpPWpGaD
Amantadine—MAOB—Metabolism—MGLL—osteoporosis	8.71e-05	0.0017	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—ANXA2—osteoporosis	8.42e-05	0.00164	CbGpPWpGaD
Amantadine—DDC—Metabolism—CYP27A1—osteoporosis	8.28e-05	0.00161	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—ADCY5—osteoporosis	8.22e-05	0.0016	CbGpPWpGaD
Amantadine—DDC—Metabolism—ACP5—osteoporosis	8.05e-05	0.00157	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PTH1R—osteoporosis	8.01e-05	0.00156	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CALCR—osteoporosis	8.01e-05	0.00156	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—IL6R—osteoporosis	7.71e-05	0.0015	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—IL6—osteoporosis	7.71e-05	0.0015	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—ADCY5—osteoporosis	7.66e-05	0.00149	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—TNF—osteoporosis	7.64e-05	0.00149	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—IL6R—osteoporosis	7.52e-05	0.00146	CbGpPWpGaD
Amantadine—DDC—Metabolism—TPI1—osteoporosis	7.48e-05	0.00146	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—PTH—osteoporosis	7.44e-05	0.00145	CbGpPWpGaD
Amantadine—MAOB—Metabolism—IDH2—osteoporosis	7.41e-05	0.00144	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CALCR—osteoporosis	7.27e-05	0.00142	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PTH1R—osteoporosis	7.27e-05	0.00142	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CNR2—osteoporosis	7.25e-05	0.00141	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—IL6—osteoporosis	7.18e-05	0.0014	CbGpPWpGaD
Amantadine—DDC—Metabolism—P4HB—osteoporosis	7.04e-05	0.00137	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CYP27A1—osteoporosis	6.97e-05	0.00136	CbGpPWpGaD
Amantadine—DDC—Metabolism—GAPDH—osteoporosis	6.91e-05	0.00134	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—WNT1—osteoporosis	6.82e-05	0.00133	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ACP5—osteoporosis	6.78e-05	0.00132	CbGpPWpGaD
Amantadine—DDC—Metabolism—RAP1A—osteoporosis	6.73e-05	0.00131	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—LEP—osteoporosis	6.57e-05	0.00128	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PKM—osteoporosis	6.44e-05	0.00125	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—FDPS—osteoporosis	6.44e-05	0.00125	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—LEP—osteoporosis	6.4e-05	0.00125	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—ADCY5—osteoporosis	6.38e-05	0.00124	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—MGLL—osteoporosis	6.36e-05	0.00124	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—ADCY5—osteoporosis	6.3e-05	0.00123	CbGpPWpGaD
Amantadine—MAOB—Metabolism—TPI1—osteoporosis	6.3e-05	0.00123	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	6.28e-05	0.00122	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—LEP—osteoporosis	6.19e-05	0.0012	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—IL6—osteoporosis	6.17e-05	0.0012	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—PTHLH—osteoporosis	6.17e-05	0.0012	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PGLS—osteoporosis	6.1e-05	0.00119	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GPD2—osteoporosis	6.1e-05	0.00119	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PKM—osteoporosis	6e-05	0.00117	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—FDPS—osteoporosis	6e-05	0.00117	CbGpPWpGaD
Amantadine—MAOB—Metabolism—P4HB—osteoporosis	5.92e-05	0.00115	CbGpPWpGaD
Amantadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	5.88e-05	0.00115	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—ADCY5—osteoporosis	5.87e-05	0.00114	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—IL6—osteoporosis	5.86e-05	0.00114	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GAPDH—osteoporosis	5.81e-05	0.00113	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MGLL—osteoporosis	5.78e-05	0.00112	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GPD2—osteoporosis	5.69e-05	0.00111	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PGLS—osteoporosis	5.69e-05	0.00111	CbGpPWpGaD
Amantadine—MAOB—Metabolism—RAP1A—osteoporosis	5.66e-05	0.0011	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PNP—osteoporosis	5.58e-05	0.00109	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ATIC—osteoporosis	5.58e-05	0.00109	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—IL6R—osteoporosis	5.51e-05	0.00107	CbGpPWpGaD
Amantadine—DDC—Metabolism—ENO1—osteoporosis	5.44e-05	0.00106	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CALCA—osteoporosis	5.43e-05	0.00106	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—IL6R—osteoporosis	5.37e-05	0.00104	CbGpPWpGaD
Amantadine—DDC—Metabolism—PSMA2—osteoporosis	5.36e-05	0.00104	CbGpPWpGaD
Amantadine—DDC—Metabolism—PSMA5—osteoporosis	5.36e-05	0.00104	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ATIC—osteoporosis	5.2e-05	0.00101	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PNP—osteoporosis	5.2e-05	0.00101	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—IL1B—osteoporosis	5.15e-05	0.001	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	4.93e-05	0.00096	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SOST—osteoporosis	4.75e-05	0.000925	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—OXCT1—osteoporosis	4.74e-05	0.000924	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CA2—osteoporosis	4.74e-05	0.000924	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—POMC—osteoporosis	4.69e-05	0.000913	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—MGLL—osteoporosis	4.62e-05	0.0009	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ENO1—osteoporosis	4.58e-05	0.000891	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PSMA2—osteoporosis	4.51e-05	0.000878	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PSMA5—osteoporosis	4.51e-05	0.000878	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CA2—osteoporosis	4.42e-05	0.000861	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—OXCT1—osteoporosis	4.42e-05	0.000861	CbGpPWpGaD
Amantadine—DDC—Metabolism—CYP19A1—osteoporosis	4.35e-05	0.000846	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—MGLL—osteoporosis	4.31e-05	0.000839	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTH1R—osteoporosis	4.29e-05	0.000836	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CALCR—osteoporosis	4.29e-05	0.000836	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PTH—osteoporosis	4.21e-05	0.000819	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CNR2—osteoporosis	4.1e-05	0.000798	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—TGFB1—osteoporosis	4.01e-05	0.00078	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—IDH2—osteoporosis	3.93e-05	0.000765	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PTH—osteoporosis	3.82e-05	0.000744	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	3.81e-05	0.000742	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—TNF—osteoporosis	3.74e-05	0.000728	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	3.73e-05	0.000726	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CNR2—osteoporosis	3.72e-05	0.000725	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP27A1—osteoporosis	3.7e-05	0.00072	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—IDH2—osteoporosis	3.66e-05	0.000713	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CYP19A1—osteoporosis	3.66e-05	0.000712	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ACP5—osteoporosis	3.6e-05	0.0007	CbGpPWpGaD
Amantadine—DDC—Metabolism—ADCY5—osteoporosis	3.55e-05	0.000692	CbGpPWpGaD
Amantadine—DDC—Metabolism—GPX1—osteoporosis	3.54e-05	0.000689	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—FDPS—osteoporosis	3.52e-05	0.000685	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PKM—osteoporosis	3.52e-05	0.000685	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—WNT1—osteoporosis	3.5e-05	0.000681	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PTHLH—osteoporosis	3.48e-05	0.000679	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP27A1—osteoporosis	3.45e-05	0.000671	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—IL6—osteoporosis	3.44e-05	0.000669	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MGLL—osteoporosis	3.41e-05	0.000664	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.39e-05	0.00066	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ACP5—osteoporosis	3.35e-05	0.000653	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—IL6—osteoporosis	3.35e-05	0.000652	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TPI1—osteoporosis	3.34e-05	0.000651	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GPD2—osteoporosis	3.33e-05	0.000649	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PGLS—osteoporosis	3.33e-05	0.000649	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—LRP5—osteoporosis	3.33e-05	0.000648	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	3.3e-05	0.000642	CbGpPWpGaD
Amantadine—DDC—Metabolism—MTHFR—osteoporosis	3.27e-05	0.000636	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—TGFB1—osteoporosis	3.25e-05	0.000634	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—LRP6—osteoporosis	3.19e-05	0.00062	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—TGFB1—osteoporosis	3.17e-05	0.000618	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PTHLH—osteoporosis	3.16e-05	0.000616	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.16e-05	0.000615	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—P4HB—osteoporosis	3.14e-05	0.000612	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TPI1—osteoporosis	3.12e-05	0.000607	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GAPDH—osteoporosis	3.08e-05	0.000601	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CALCA—osteoporosis	3.07e-05	0.000597	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PNP—osteoporosis	3.05e-05	0.000594	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ATIC—osteoporosis	3.05e-05	0.000594	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—TNF—osteoporosis	3.04e-05	0.000592	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—RAP1A—osteoporosis	3e-05	0.000585	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ADCY5—osteoporosis	2.99e-05	0.000582	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GPX1—osteoporosis	2.98e-05	0.00058	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—TNF—osteoporosis	2.96e-05	0.000577	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—P4HB—osteoporosis	2.93e-05	0.00057	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GAPDH—osteoporosis	2.88e-05	0.00056	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—POMC—osteoporosis	2.84e-05	0.000553	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—RAP1A—osteoporosis	2.8e-05	0.000545	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CALCA—osteoporosis	2.79e-05	0.000542	CbGpPWpGaD
Amantadine—MAOB—Metabolism—MTHFR—osteoporosis	2.75e-05	0.000535	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TLN1—osteoporosis	2.69e-05	0.000524	CbGpPWpGaD
Amantadine—DDC—Metabolism—POMC—osteoporosis	2.61e-05	0.000509	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—OXCT1—osteoporosis	2.59e-05	0.000505	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CA2—osteoporosis	2.59e-05	0.000505	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—MGLL—osteoporosis	2.53e-05	0.000492	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—IL6—osteoporosis	2.45e-05	0.000477	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ENO1—osteoporosis	2.43e-05	0.000473	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PSMA5—osteoporosis	2.39e-05	0.000466	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PSMA2—osteoporosis	2.39e-05	0.000466	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—IL6—osteoporosis	2.39e-05	0.000465	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—P4HB—osteoporosis	2.32e-05	0.000452	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—IL6—osteoporosis	2.31e-05	0.00045	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ENO1—osteoporosis	2.26e-05	0.000441	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTH—osteoporosis	2.26e-05	0.000439	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PSMA2—osteoporosis	2.23e-05	0.000434	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PSMA5—osteoporosis	2.23e-05	0.000434	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RAP1A—osteoporosis	2.22e-05	0.000432	CbGpPWpGaD
Amantadine—MAOB—Metabolism—POMC—osteoporosis	2.2e-05	0.000428	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CNR2—osteoporosis	2.2e-05	0.000428	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—ADCY5—osteoporosis	2.18e-05	0.000425	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NFATC1—osteoporosis	2.16e-05	0.000421	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—IDH2—osteoporosis	2.15e-05	0.000418	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—DKK1—osteoporosis	2.15e-05	0.000418	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—WNT1—osteoporosis	2.07e-05	0.000403	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP27A1—osteoporosis	2.02e-05	0.000393	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGA—osteoporosis	2.01e-05	0.000392	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—ADCY5—osteoporosis	1.98e-05	0.000386	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.98e-05	0.000386	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.98e-05	0.000385	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ACP5—osteoporosis	1.96e-05	0.000382	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP19A1—osteoporosis	1.94e-05	0.000378	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—BMP2—osteoporosis	1.87e-05	0.000364	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTHLH—osteoporosis	1.87e-05	0.000364	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.85e-05	0.00036	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.85e-05	0.000359	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGB—osteoporosis	1.83e-05	0.000356	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TPI1—osteoporosis	1.83e-05	0.000356	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP19A1—osteoporosis	1.81e-05	0.000352	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PSMA2—osteoporosis	1.77e-05	0.000344	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PSMA5—osteoporosis	1.77e-05	0.000344	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—P4HB—osteoporosis	1.72e-05	0.000334	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GAPDH—osteoporosis	1.69e-05	0.000328	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CALCA—osteoporosis	1.65e-05	0.00032	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—RAP1A—osteoporosis	1.64e-05	0.00032	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—POMC—osteoporosis	1.61e-05	0.000313	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ADCY5—osteoporosis	1.59e-05	0.000309	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GPX1—osteoporosis	1.58e-05	0.000308	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KL—osteoporosis	1.49e-05	0.000291	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ADCY5—osteoporosis	1.48e-05	0.000288	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GPX1—osteoporosis	1.47e-05	0.000287	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—MTHFR—osteoporosis	1.46e-05	0.000284	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—POMC—osteoporosis	1.46e-05	0.000284	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL6R—osteoporosis	1.42e-05	0.000277	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—MTHFR—osteoporosis	1.36e-05	0.000265	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ENO1—osteoporosis	1.33e-05	0.000258	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PSMA2—osteoporosis	1.31e-05	0.000255	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PSMA5—osteoporosis	1.31e-05	0.000255	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ADCY5—osteoporosis	1.17e-05	0.000228	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—POMC—osteoporosis	1.17e-05	0.000227	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SPP1—osteoporosis	1.13e-05	0.000221	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—POMC—osteoporosis	1.09e-05	0.000212	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP19A1—osteoporosis	1.06e-05	0.000207	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IRS2—osteoporosis	1.02e-05	0.000199	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—LEP—osteoporosis	1e-05	0.000195	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ESR1—osteoporosis	9.57e-06	0.000186	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IRS1—osteoporosis	8.94e-06	0.000174	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ADCY5—osteoporosis	8.67e-06	0.000169	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GPX1—osteoporosis	8.64e-06	0.000168	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—POMC—osteoporosis	8.61e-06	0.000168	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL6R—osteoporosis	8.4e-06	0.000164	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IGF1—osteoporosis	8.28e-06	0.000161	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—MTHFR—osteoporosis	7.97e-06	0.000155	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—POMC—osteoporosis	6.37e-06	0.000124	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL6—osteoporosis	6.33e-06	0.000123	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MYC—osteoporosis	4.98e-06	9.69e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TGFB1—osteoporosis	4.97e-06	9.67e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL6—osteoporosis	3.74e-06	7.29e-05	CbGpPWpGaD
